Novartis and Molecular Partners’ Ensovibep Flunks In ACTIV-3 In Hospitalized COVID-19 Patients
Hopes Turn To Non-Hospitalized Patients
Ensovibep failed to meet thresholds for continued enrollment in the large NIH Phase III trial, forcing Novartis and Molecular to home in on the early COVID-19 setting instead.
You may also be interested in...
Efforts to find new uses for old drugs in COVID-19 patients are gathering pace.
The DARPin candidate will not gain emergency approval before early 2022, but its likely ability to sustain efficacy regardless of SARS-CoV-2 mutations could be valuable as new variants emerge.
The company’s lead candidate, AP1189, has shown promise in a mid-stage rheumatoid arthritis study, sparking plans for an imminent strategic business collaboration.